•
Jun 30, 2022

ICU Medical Q2 2022 Earnings Report

Announced second quarter 2022 results and updated FY 2022 guidance.

Key Takeaways

ICU Medical's second quarter 2022 revenue was $561.0 million, compared to $321.7 million in the same period last year. GAAP net loss for the second quarter of 2022 was $(7.5) million, or $(0.31) per diluted share. The company updated its full year 2022 guidance of adjusted EBITDA from a range of $450 million to $500 million to a range of $350 million to $370 million and adjusted diluted earnings per share from a range of $9.00 to $10.50 to a range of $6.20 to $6.80.

Second quarter 2022 revenue was $561.0 million, compared to $321.7 million in the same period last year.

GAAP gross profit for the second quarter of 2022 was $167.6 million, as compared to $123.5 million in the same period last year.

GAAP net loss for the second quarter of 2022 was $(7.5) million, or $(0.31) per diluted share, as compared to GAAP net income of 28.4 million, or $1.31 per diluted share, for the second quarter of 2021.

Adjusted diluted earnings per share for the second quarter of 2022 was $1.37 as compared to $1.88 for the second quarter of 2021.

Total Revenue
$561M
Previous year: $322M
+74.4%
EPS
$1.37
Previous year: $1.88
-27.1%
Adjusted EBITDA
$84.7M
Previous year: $66.9M
+26.7%
Gross Margin
30%
Previous year: 38%
-21.1%
Gross Profit
$168M
Previous year: $124M
+35.7%
Cash and Equivalents
$256M
Previous year: $462M
-44.7%
Free Cash Flow
-$85.8M
Previous year: $39.1M
-319.5%
Total Assets
$4.59B
Previous year: $1.8B
+154.6%

ICU Medical

ICU Medical

ICU Medical Revenue by Segment

Forward Guidance

The Company is updating its full year 2022 guidance of adjusted EBITDA from a range of $450 million to $500 million to a range of $350 million to $370 million and adjusted diluted earnings per share from a range of $9.00 to $10.50 to a range of $6.20 to $6.80.

Revenue & Expenses

Visualization of income flow from segment revenue to net income